home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 11/11/20

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - CytoDyn Completes Second Non-dilutive $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants to Help Expedite License Applications Here and Abroad and Successful COVID-19 Trials

VANCOUVER, Washington, Nov. 11, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announ...
CYDY - CytoDyn to Hold Webcast on November 5 to Update Clinical and Regulatory Developments

VANCOUVER, Washington, Nov. 02, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announ...

CYDY - Generex Sees Way Forward With Long-Lasting Covid-19 Vaccine

Ii-Key technology is safe, and in a breast cancer trial 10 years out, still effective. GNBT is negotiating contracts covering these areas: Malaysia, New Zealand, Australia, Southeast Asia, Singapore, South Africa, China, and Canada. Three trials of its vaccine are in the offing - ...

CYDY - Regeneron's Positive Dupixent Data, And Other News: The Good, Bad And Ugly Of Biopharma

Regeneron reports positive data for Dupixent pivotal trial. CytoDyn reports encouraging data for Leronlimab in stroke patients. Turning Point Therapeutics announces positive results from TPX-0022 trial. For further details see: Regeneron's Positive Dupixent Data, And Oth...
CYDY - Cytodyn to file marketing application for leronlimab as combination therapy for HIV in U.K.

The Medicines & Healthcare product Regulatory Agency ((MHRA)) of the U.K. government has cleared CytoDyn (CYDY) to file its Biologics License Application ((BLA)) for leronlimab as a combination therapy for multi-drug resistance HIV patients. The clearance included a treatment regimen of o...

CYDY - U.K. MHRA Clears CytoDyn to File its BLA for Leronlimab as One Injection per Week for Combination HIV Therapy

VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announ...

CYDY - CytoDyn's leronlimab shows encouraging action in stroke patients

CytoDyn (CYDY) announces promising early responses in two patients recovering from strokes.One patient experienced improved sensations in his body and face and the other experienced improvement in her partial paralysis.Chairman, CMO and Head of Business Development Scott Kelly, M.D., says, &#...
CYDY - Leronlimab Shows Early, but Promising Clinical Responses in First Two Patients Recovering from Stroke

VANCOUVER, Washington, Oct. 26, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announ...

CYDY - CytoDyn Appoints Mahboob Rahman, M.D., Ph.D., as Chief Scientific Officer

Dr. Rahman’s 18 years of pharmaceutical industry experience is highlighted by 16 successful BLA/NDAs and sBLAs VANCOUVER, Washington, Oct. 21, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company"), a late-stage biotechnol...

CYDY - CytoDyn study of leronlimab for COVID-19 passes first safety review

The independent Data Safety Monitoring Committee ((DSMC)) has completed its first interim analysis of a Phase 2b/3 clinical trial evaluating CytoDyn's (CYDY) leronlimab in severe-to-critical COVID-19 patients. The analysis was performed on data from the first 50% (n=195) of participants.The D...
Previous 10 Next 10